848 related articles for article (PubMed ID: 15469413)
1. Rationale and study design of the CardioGene Study: genomics of in-stent restenosis.
Ganesh SK; Skelding KA; Mehta L; O'Neill K; Joo J; Zheng G; Goldstein J; Simari R; Billings E; Geller NL; Holmes D; O'Neill WW; Nabel EG
Pharmacogenomics; 2004 Oct; 5(7):952-1004. PubMed ID: 15469413
[TBL] [Abstract][Full Text] [Related]
2. Optical coherence tomography (OCT) in PCI for in-stent restenosis (ISR): rationale and design of the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) study.
Adriaenssens T; Dens J; Ughi G; Coosemans M; Onsea K; Dubois C; Sinnaeve P; Vrolix M; Desmet W
EuroIntervention; 2011 May; 7 Suppl K():K100-5. PubMed ID: 22027717
[TBL] [Abstract][Full Text] [Related]
3. Contemporary treatment of in-stent restenosis and the incidence of recurrent in-stent restenosis in the era of drug-eluting stents.
Ajani AE; Yan BP; Clark DJ; Eccleston D; Walton A; Lew R; Meehan A; Brennan A; Reid C; Duffy SJ;
Heart Lung Circ; 2007 Aug; 16(4):269-73. PubMed ID: 17419097
[TBL] [Abstract][Full Text] [Related]
4. Role of Gene Polymorphisms/Haplotypes and Plasma Level of TGF-β1 in Susceptibility to In-Stent Restenosis Following Coronary Implantation of Bare Metal Stent in Chinese Han Patients.
Chen HJ; Mo N; Zhang YF; Su GZ; Wu HD; Pei F
Int Heart J; 2018 Jan; 59(1):161-169. PubMed ID: 29332922
[TBL] [Abstract][Full Text] [Related]
5. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
[TBL] [Abstract][Full Text] [Related]
6. Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent.
Zeng WP; Zhang R; Li R; Luo JF; Hu XF
PLoS One; 2017; 12(1):e0170964. PubMed ID: 28129392
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
8. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.
Habara S; Iwabuchi M; Inoue N; Nakamura S; Asano R; Nanto S; Hayashi Y; Shiode N; Saito S; Ikari Y; Kimura T; Hosokawa J; Nakamura M; Kotani J; Kozuma K; Mitsudo K
Am Heart J; 2013 Sep; 166(3):527-33. PubMed ID: 24016503
[TBL] [Abstract][Full Text] [Related]
9. Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study.
Alfonso F; Cuesta J; Pérez-Vizcayno MJ; García Del Blanco B; Rumoroso JR; Bosa F; Pérez de Prado A; Masotti M; Moreno R; Cequier A; Gutiérrez H; García Touchard A; López-Mínguez JR; Zueco J; Martí V; Velázquez M; Morís C; Bastante T; García-Guimaraes M; Rivero F; Fernández C;
JACC Cardiovasc Interv; 2017 Sep; 10(18):1841-1851. PubMed ID: 28866036
[TBL] [Abstract][Full Text] [Related]
10. High rate of in-stent restenosis after coronary intervention in carriers of the mutant mannose-binding lectin allele.
Bagyura Z; Kiss L; Berta B; Szilágyi Á; Hirschberg K; Széplaki G; Lux Á; Szelid Z; Soós P; Merkely B
BMC Cardiovasc Disord; 2017 Jan; 17(1):4. PubMed ID: 28056798
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of drug-eluting balloon in patients with bare-metal or drug-eluting stent restenosis.
Berta B; Jambrik Z; Kohar K; Szabo G; Ruzsa Z; Molnar L; Barczi G; Geller L; Becker D; Merkely B
Hellenic J Cardiol; 2014; 55(5):369-77. PubMed ID: 25243435
[TBL] [Abstract][Full Text] [Related]
12. Integrity(®) bare-metal coronary stent-induced platelet and endothelial cell activation results in a higher risk of restenosis compared to Xience(®) everolimus-eluting stents in stable angina patients.
Szük T; Fejes Z; Debreceni IB; Kerényi A; Édes I; Kappelmayer J; Nagy B
Platelets; 2016 Jul; 27(5):410-9. PubMed ID: 26765134
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme insertion/deletion polymorphism does not influence the restenosis rate after coronary stent implantation.
Ferrari M; Mudra H; Grip L; Voudris V; Schächinger V; de Jaegere P; Rieber J; Hausmann D; Rothman M; Koschyk DH; Figulla HR;
Cardiology; 2002; 97(1):29-36. PubMed ID: 11893827
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
[TBL] [Abstract][Full Text] [Related]
15. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
Zhao K; Li YJ; Gao S
Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
[TBL] [Abstract][Full Text] [Related]
17. Everolimus- and zotarolimus-eluting stents for bare metal stent in-stent restenosis treatment: a prospective study.
Toutouzas K; Patsa C; Tsiamis E; Tsioufis C; Spanos A; Stefanadi E; Tentolouris C; Stefanadis C
J Interv Cardiol; 2008 Oct; 21(5):388-94. PubMed ID: 18705639
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of the CHA2DS2-VASc Score in Predicting In-Stent Restenosis Among Patients Undergoing Revascularization With Bare-Metal Stents.
Kurtul A
Clin Appl Thromb Hemost; 2018 May; 24(4):589-595. PubMed ID: 28675046
[TBL] [Abstract][Full Text] [Related]
19. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
